The antiviral properties of lactoferrin makes it a great natural supplement that could also be used as an adjunct for COVID-19 and for various other Respiratory Tract Infections (RTIs) according to a team of researchers led by the University of…
Read More
Respiratory virus detections decreased during COVID-19
(HealthDay)—Respiratory virus detections decreased during the COVID-19 pandemic period, according to a research letter published online June 21 in JAMA Internal Medicine. Alexander J. Lepak, M.D., from the University of Wisconsin School of Medicine and Public Health in Madison, and…
Read More
Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines
Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019…
Read More
Can biomaterials offer novel therapeutic strategies against COVID-19?
The global coronavirus disease 2019 (COVID-19) pandemic rages on. To date, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has infected over 138.3 million and caused over 2.9 million deaths the world over. Despite major gains…
Read More
Experimental evidence that ADAM17 inhibition prevents severe COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus that is contagious in humans. It is the causal agent of the ongoing coronavirus 2019 (COVID-19) pandemic. This virus causes a mild to severe infection and has…
Read More
Researchers identify SARS-CoV-2 antiviral compounds using protein assay
On March 11, 2020, the World Health Organization (WHO) announced the coronavirus disease 2019 (COVID-19) to be a pandemic. COVID-19 is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen, which is deemed to be highly contagious…
Read More
Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape
The current pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered an intensive hunt for effective new and repurposed antivirals and antibodies, for prevention and treatment of the infection. A new preprint…
Read More
Researchers explore an inhalable SARS-CoV-2 nanobody therapy
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the world’s third major coronavirus outbreak. To date, the SARS-CoV-2 has infected over 135 million lives and caused over 2.9 million deaths. Even…
Read More
Researchers discover a new monoclonal antibody that is effective against SARS-CoV-2 variants
A new monoclonal antibody targets a particular region of the receptor-binding domain (RBD) on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This region is usually not accessible to immune cells, which may be why it has broad neutralizing capabilities….
Read More
Research surveys hygiene practices in food supply chains during COVID-19 pandemic
With the onset of the coronavirus disease 2019 (COVID-19) pandemic, many worried they could be exposed to its causative pathogen – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – through their food. While more research has suggested transmission through food…
Read More